Advances in Obstetrics and Gynecology Research

Effectiveness and Safety of Low-flow Sevoflurane Combined with Remifentanil on Anaesthesia of Patients Undergoing Gynaecological Laparoscopic Surgery

Liping Sun — Mon, 04 Nov 2024 13:19:22 +0800

Objective: To evaluate the advantages of sevoflurane (low-flow) + remifentanil for patients undergoing gynaecological laparoscopic surgery. Methods: 300 patients admitted for gynaecological laparoscopic surgery between July 2020 and July 2023 were selected and divided equally by random number table, 150 cases were counted in the observation group, and sevoflurane (low-flow) + remifentanil was chosen for maintenance anaesthesia; 150 cases were counted in the reference group, and anaesthesia was maintained only with remifentanil. The anaesthesia indexes, haemodynamics, stress reaction indexes, and adverse reaction rate of the two groups were compared. Results: The anaesthesia indexes of the observation group were better than those of the reference group (P < 0.05). Before 5 min of anaesthesia (T1), there was no difference between the haemodynamics and stress reaction indexes of the two groups (P > 0.05). After 30 min of pneumoperitoneum (T2) and immediately after the end of surgery (T3), the hemodynamic and stress indicators of the observation group were lower than those of the reference group (P < 0.05). The adverse reaction rate of the observation group was lower than that of the reference group (P < 0.05). Conclusion: Sevoflurane (low-flow) + remifentanil can improve the anaesthesia indexes of gynecological laparoscopic surgery patients, stabilize intraoperative haemodynamics, reduce the stress reaction, and the safety of medication is high.

Investigation of Female Menopausal Syndrome and Cognition of Hormone Replacement Therapy

Xinli Mao, Qian Li, Changhua Zhao, Zixuan Zhang — Mon, 04 Nov 2024 13:25:43 +0800

Objective: To investigate the incidence of female menopausal syndrome and the cognition of hormone replacement therapy (HRT), providing a basis for interventions for menopausal syndrome in women. Methods: From October 2021 to June 2023, a survey was conducted mainly in Guangzhou’s Huangpu District, using a cluster random sampling method to select 3,000 women who voluntarily participated. A questionnaire was used to collect general information about the participants and their awareness of HRT. Results: All 3,000 participants completed the questionnaire. The majority were aged 46–50 (51.90%), most were workers (24.40%), had a high school education (40.17%), and were married (91.20%). The most common symptoms of menopausal syndrome were insomnia, fatigue, and joint/muscle pain, with prevalence rates of 71.23%, 66.57%, and 63.57%, respectively, significantly higher than other symptoms (P < 0.05). Other symptoms included depression, mood swings, palpitations, hot flashes, and sweating. Among the participants, 64.93% were unaware of HRT, 11.63% had heard of it, 9.40% were very familiar with it, and 14.03% had used it. Healthcare professionals were the main source of HRT knowledge for the participants, with other sources including the internet, friends, media, and lectures. The moderate and severe symptom groups included 1,832 and 1,168 participants, respectively. In the severe group, follicle-stimulating hormone and luteinizing hormone levels were significantly higher than in the moderate group (P < 0.05), and estradiol levels were significantly lower than in the moderate group (P < 0.05). Conclusion: The incidence of menopausal syndrome is high among middle-aged women, with common symptoms including insomnia, fatigue, and joint/muscle pain. These symptoms may be related to hormone levels. Many women lack awareness of HRT for the menopausal syndrome, with healthcare professionals being the primary source of information. To ensure women’s physical and mental health, it is necessary to strengthen education and raise awareness of health care, emphasizing early prevention and intervention to improve the quality of life for middle-aged and elderly women.

Exploring the Role of Cuprotosis-Associated Genes in Cancer Progression and Therapy Resistance: A Comprehensive Analysis across Multiple Cancer Types

Yasir Hameed — Thu, 31 Oct 2024 00:00:00 +0800

This review presents a comprehensive overview of the role of cuprotosis-associated genes in various cancer types, highlighting their significance in tumor progression and therapy resistance. In breast cancer and colorectal cancer (CRC), dysregulation of genes involved in mitochondrial function and copper metabolism, such as FDX1, LIAS, LIPT1, DLD, DLAT, and PDHA1/PDHB, promotes metabolic reprogramming and enhances cancer cell survival. Ovarian cancer exhibits unique dysregulations in genes like ATP7B, CCS, and COMMD1, influencing copper metabolism and redox signaling pathways, thereby contributing to chemoresistance and tumor growth. Head and neck cancer involves upregulation of MT1X, ATP7A, and CCS, potentially aiding cancer cell survival under oxidative stress conditions. Lung cancer is characterized by distinct dysregulation of genes like SLC31A1, ATOX1, and COMMD1, modulating copper homeostasis and redox signaling to support tumor proliferation. Liver cancer and kidney cancer each present unique sets of dysregulated cuprotosis-associated genes, such as SLC39A4, SCO2, and ATP7A, suggesting novel therapeutic targets specific to these cancer types. Pathway analysis reveals enrichment in mineral absorption pathways, emphasizing the importance of these genes in maintaining cellular mineral homeostasis. Understanding the intricate interplay between cuprotosis-associated genes and cancer biology offers insights into potential therapeutic strategies targeting copper metabolism for improved treatment outcomes across various cancer types.